Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02852655 · ClinicalTrials.gov registry record · Phase 1
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
A Phase 1 study of Brain Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT02852655 is a Phase 1 study of Brain Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT02852655, a Phase 1 study of Brain Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
Conditions Studied
Interventions
- DRUG MK-3475
Study Locations (7)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer - New York
Texas
- UT, MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02852655
The ClinicalTrials.gov registry entry for NCT02852655 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-3475 is the first listed.
NCT02852655 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02852655 about?
NCT02852655 is a clinical study titled "A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma". This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
What is the current status of trial NCT02852655?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09-21. Estimated completion is 2026-07-31.
What conditions does trial NCT02852655 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT02852655?
The interventions under investigation include: MK-3475 (DRUG).
Who is sponsoring clinical trial NCT02852655?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02852655 being conducted?
This trial has 7 study locations across California, Massachusetts, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.